

# “Investment In Innovation (In<sup>3</sup>)”

medtech  insight  
a division of Windhover Information

A PREVIEW OF EARLY-STAGE  
MEDICAL TECHNOLOGY COMPANIES

## Grant Life Sciences developing cervical cancer blood test that detects presence of antibodies produced only by cancer-causing HPV types

by Ronald C. Trahan

According to Grant Life Sciences, traditional and liquid ‘Pap’ tests for cervical cancer have significant limitations. While acknowledging that Pap tests have helped reduce deaths caused by cervical cancer, the Company points out that Pap tests have limited predictive value—9 million colposcopies are performed annually worldwide on patients with abnormal Pap test results, but only about 20% reveal cervical cancer or pre-cancerous conditions. The Company also believes that HPV tests also have significant shortcomings in cervical cancer screening. “While HPV DNA-testing is helpful in detecting the presence of HPV—which is a precursor for virtually all cervical cancer—nonetheless HPV tests have limited predictive value: only two percent of patients who test positive for HPV will eventually contract cervical cancer,” says David Bolick, M.D., medical director for Grant Life Sciences. “And, like the invasive Pap test, an HPV test requires a physician or other healthcare professional to extract cells from the cervix, which may inhibit some women in non-Western cultures from undergoing screening.”



Stan Yakatan  
Chairman and CEO,  
Grant Life Sciences  
(OTC BB: “GLIF”)

**Grant Life Sciences’ planned cervical cancer blood tests will detect the presence of antibodies produced only by cancer-causing HPV types.** “There are some 100 types of HPV,” says Dr. Bolick. “However, only about 7 to 15 HPV-types cause most cervical cancers. Cancer-causing HPV-types express certain unique proteins that trigger the disease and can be readily distinguished from antibodies produced in reaction to non-cancer-causing HPV-types.” **By detecting presence of antibodies to only cancer-causing HPV-types, Grant Life Sciences expect its tests to more reliably determine whether a patient has cervical cancer or pre-cervical cancer conditions.** Preliminary experimental results show Grant’s first-generation blood test, AbREACT™, to be substantially more accurate than currently available tests. In preliminary studies that used Grant’s patented AbReact™ test to analyze blood samples of 70 patients, AbReact™ was able to detect cervical cancer or pre-cancerous conditions with 97 percent sensitivity (29/30), and able to ‘rule out’ cervical cancer or pre-cancerous conditions with 85 percent specificity (34/41). The Company expects Ab-REACT™ to be an industry-standard ELISA (Enzyme Linked Immunosorbent Assay) format run in a clinical laboratory setting. “The blood specimen is sent to a lab, where a technician runs the test using readily available equipment,” says Dr. Bolick. While test results typically are available in about two hours, it is expected that the typical turnaround time from the lab to the doctor will be approximately one day. It also is expected that a doctor will be able to order AbREACT™ as one of a battery of tests run on a patient’s blood sample.

**Grant’s Chairman and CEO is Stan Yakatan**, who has founded or co-founded 15 companies in the U.S., Canada, Israel, France and Germany. He also has advised on numerous acquisitions and corporate finance transactions, raising in excess of \$1 billion in public and private capital markets. His experience includes positions with New England Nuclear, El Dupont, ICN Pharma, and New Brunswick Scientific. “Medtech Insight meetings are absolutely among the very best in the life sciences industry,” says Yakatan. “I am impressed with the quality of investors who attend and am eagerly looking forward to presenting at the upcoming San Francisco meeting.”

### What leading investors are saying about Medtech Insight’s In<sup>3</sup> events:



*“I look forward to attending Medtech Insight’s conferences because I know that in a short period of time, I can evaluate a significant number of companies presenting their story. I have little time, but Medtech Insight provides the opportunity to vet a lot of ideas.”*

Renee Compton Ryan  
Managing Director  
Broadview International



*“I have found that Medtech Insight meetings are a great forum in which to get up close and personal with potentially great companies if I choose. Lots of great opportunities are placed in front of me in just a day and a half, thus maximizing my deal-screening efficiency.”*

Timothy Petersen  
Managing Partner  
Arboretum Ventures



*“I like the format in which Medtech Insight organizes its investor meetings. Giving 50 companies 10 minutes each to persuade me that they have something with large commercial potential is appealing. And I’m glad Medtech Insight is now also orchestrating topic-oriented meetings.”*

Dr. Wei Li  
Associate  
Baird Venture Partners

**Ronald C. Trahan is President/CEO of Ronald Trahan Associates Inc. ([www.ronaldtrahan.com](http://www.ronaldtrahan.com)), a public relations/investor relations firm that serves big and small companies, both public and private.**

### Investment In Innovation (In<sup>3</sup>): A Preview of Early-Stage Medical Technology Companies The Palace Hotel, San Francisco, California, June 14-15, 2005

Medtech Insight’s In<sup>3</sup> conferences have drawn a total of more than 4,400 senior execs from the investment community and major medtech companies, and have featured more than 500 innovative early-stage presenting companies. In<sup>3</sup> San Francisco will, once again, feature a new group of over 50 early-stage medical technology companies seeking partnering and/or investment.

To register for this conference, please call 949-219-0150 or 888-290-2225 (toll-free in the U.S.), send an email to [in3@medtechinsight.com](mailto:in3@medtechinsight.com), or register online at [www.medtechinsight.com](http://www.medtechinsight.com).